5 results found.

Schizophrenia, or Impaired Cognition Clinical Trial using EVP-6124

EnVivo Pharmaceuticals, Inc. - Recruiting 18 years to 50 years.
- A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to Two Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects With Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy.
EVP-6124

Schizophrenia, or Impaired Cognition Clinical Trial using EVP-6124; Placebo

EnVivo Pharmaceuticals, Inc. - Recruiting 18 years to 50 years.
- A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy.
EVP-6124; Placebo

Schizophrenia, or Impaired Cognition Clinical Trial using EVP-6124; Placebo

EnVivo Pharmaceuticals, Inc. - Recruiting 18 years to 50 years.
- A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy.
EVP-6124; Placebo

Impaired Cognition Clinical Trial using physical activity

Fundacion para la Investigacion y Formacion en Ciencias de la Salud - Recruiting 18 years or older.
- Physical Activity Program for Patients With Dementia and Their Relative Caregivers. Randomized Clinical Trial in Primary Health Care. APISDEMyF.
physical activity

Brain Ischemia, Adverse Effect of Thrombolytic Drugs, Impaired Co Clinical Trial

University Hospital, Lille - Recruiting 18 years or older.
- Influence of the Pre-existing Cognitive Status on the Outcome in Patients Treated by Thrombolytic Therapy for Acute Cerebral Ischaemia.